Picard Medical, Inc. (PMI) stock
PMINYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3076% above fair value
$6.91−0.33 (-4.56%)
Close on Nov 17, 2026Market cap $16.16MP/E –Yield –
Picard Medical r&d expenses
Research and development expenses are spending on new products and technology.
Picard Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.14M, up 25.7% year over year. For fiscal 2025 it was $3.05M, down 9.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.05M | -9.8% |
| FY2024 | Dec 31, 2024 | $3.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $321.00K | -66.2% |
| Q2 FY2026 | Jun 30, 2026 | $1.37M | +84.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.90M | +134.5% |
| Q4 FY2025 | Dec 31, 2025 | $547.00K | -30.7% |
| Q3 FY2025 | Sep 30, 2025 | $951.00K | -1.0% |
| Q2 FY2025 | Jun 30, 2025 | $743.00K | -21.0% |
| Q1 FY2025 | Mar 31, 2025 | $808.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $789.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $961.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $940.00K | – |
See a number that looks wrong?